Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006227
Status:
COMPLETED
Last Update Posted:
2020-03-05
First Post:
2000-09-11
Brief Title:
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Sponsor:
Gynecologic Oncology Group
Organization:
GOG Foundation
Study Overview
Official Title:
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
PRIMARY OBJECTIVES
I To estimate the probability of clinical response and toxicity of paclitaxel as second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma
II To evaluate the value of inhibin for predicting response
OUTLINE
Patients receive paclitaxel intravenously IV over 3 hours on day 1 Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years then every 6 months for three years and then annually thereafter
I To estimate the probability of clinical response and toxicity of paclitaxel as second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma
II To evaluate the value of inhibin for predicting response
OUTLINE
Patients receive paclitaxel intravenously IV over 3 hours on day 1 Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years then every 6 months for three years and then annually thereafter
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA027469 | NIH | CTEP | httpsreporternihgovquickSearchU10CA027469 |
| NCI-2011-02054 | REGISTRY | None | None |
| GOG 0187 | None | None | None |
| CDR0000068149 | None | None | None |
| GOG-0187 | None | None | None |
| GOG-0187 | OTHER | None | None |
| GOG-0187 | OTHER | None | None |
| U10CA180868 | NIH | None | None |